Every Form 4 that Anavex Life Sciences (AVXL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVXL filings page.
Anavex Life Sciences reported that President and CEO Christopher Missling had 125,000 stock options vest on January 6, 2026. These options have an exercise price of $8.58 per share and are shown as acquired at a price of $0, reflecting the vesting of an existing award rather than a market purchase. The options are part of a larger grant made on March 31, 2025 covering 500,000 shares, structured to vest in four equal performance-based tranches.
One milestone for this grant was achieving a Second Regulatory dialogue for blarcamesine. The filing states that the performance criteria for this milestone were met, causing this 125,000-share tranche to vest. Following the transaction, Missling directly holds 125,000 derivative securities (stock options), each representing one share of common stock, with an expiration date of March 31, 2035.
Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026. The option covers 12,500 shares of common stock at an exercise price of $8.58 per share and is exercisable until March 31, 2035.
The 12,500-share tranche comes from an earlier option grant dated March 31, 2025 for 50,000 shares that vests in four equal performance-based tranches. One milestone was achieving a second regulatory dialogue for blarcamesine, and meeting this performance criterion triggered vesting of this 12,500-share portion, which Boenisch now holds directly.
Sandra Boenisch, the PFO & Treasurer of Anavex Life Sciences Corp. (AVXL), reported a change in beneficial ownership on 10/02/2025. A derivative transaction shows acquisition of 12,500 shares underlying a stock option at an exercise price of $5.36. After the transaction, the filing reports 25,000 shares beneficially owned directly by Ms. Boenisch. The filing explains the option was originally granted on 02/20/2024 for 50,000 shares and vests in four equal tranches tied to performance milestones; one milestone (readout of the AV3-71-SZ-001 schizophrenia study) was met, causing vesting of the 12,500 tranche.
Anavex Life Sciences (AVXL) disclosed that President and CEO Christopher Missling had 125,000 stock options vest on 10/02/2025. The options carry an exercise price of $5.36 and expire on 02/20/2034.
These options are part of a 500,000-share grant made on 02/20/2024 that vests in four equal tranches tied to performance milestones, including the readout of the AV3-71-SZ-001 schizophrenia study, which was met, triggering this vesting tranche.
Following the reported transaction, 250,000 derivative securities were beneficially owned.